BOXED WARNING Suicidality—increased risk of suicidal thinking and behavior in children, adolescents, and young adults; not approved for pediatric use. Monitor for clinical worsening.
FDA dosing
Population
Start
Target
Max
Depression
Adult outpatient
75 mg/day divided (or 50–100 mg QHS)
50–100 mg/day
150 mg/day
Depression
Adult hospitalized
100 mg/day
—
200–300 mg/day
Depression
Adolescent/elderly
10 mg TID + 20 mg QHS
—
—
Renal Undefined
Hepatic Undefined
Instructions
Initiate low and increase gradually; maintenance may be given as a single bedtime dose.
Taper gradually to discontinue (abrupt cessation may cause nausea, headache, malaise).
Allow ≥14 days after stopping an MAOI before starting; not recommended during acute post-MI recovery.
Contraindications
MAOIs (concurrently or within 14 days) due to risk of hyperpyretic crises, severe convulsions, and death
Concomitant cisapride (increased QT interval and arrhythmia risk)
Acute recovery phase following myocardial infarction (not recommended)
“Amy tripping off the Elevator” Polka dots on pink → α1 blocker → syncope if titrated too quickly (hit the floor) “Red as a beet” crimson color theme → anticholinergic Crown → antihistamine